Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 11/20 | 0.75 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.56 |
| ▸ | FAAH | O00519 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.51 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.50 |
| ▸ | CPT2 | P23786 | 1/20 | 0.49 |
| ▸ | CPT1A | P50416 | 1/20 | 0.49 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19717680 | 1.00 | NOD1 (0.75) | NOD1SLC6A5FAAHMEN1MAPK1 | |
| SCHEMBL26997839 | 1.00 | NOD1 (0.75) | NOD1SLC6A5FAAHMEN1MAPK1 | |
| SCHEMBL333310 | 1.00 | NOD1 (0.75) | NOD1SLC6A5FAAHMEN1MAPK1 | |
| SCHEMBL93869 | 1.00 | NOD1 (0.75) | NOD1SLC6A5FAAHMEN1MAPK1 | |
| SCHEMBL322950 | 1.00 | NOD1 (0.75) | NOD1SLC6A5FAAHMEN1MAPK1 | |
| SCHEMBL29326 | 1.00 | NOD1 (0.75) | NOD1SLC6A5FAAHMEN1MAPK1 | |
| SCHEMBL17204500 | 1.00 | NOD1 (0.75) | NOD1SLC6A5FAAHMEN1MAPK1 | |
| SCHEMBL1899588 | 1.00 | NOD1 (0.75) | NOD1SLC6A5FAAHMEN1MAPK1 | |
| SCHEMBL284836 | 1.00 | NOD1 (0.75) | NOD1SLC6A5FAAHMEN1MAPK1 | |
| SCHEMBL414654 | 0.98 | NOD1 (0.73) | NOD1SLC6A5FAAHMEN1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2263643-A2 | Anti-wrinkle cosmetic product comprising plant extracts | Henkel AG & Co. KGaA (DE) | 2010-12-22 | — | — | EP | claimed |
| EP-2243464-A2 | Skin treatment fighting skin aging I | Henkel AG & Co. KGaA (DE) | 2010-10-27 | — | — | EP | claimed |
| EP-1393518-B1 | ARYLSULFATASE-INHIBITORS IN DEODORANTS AND ANTIPERSPIRANTS | HENKEL AG & CO KGAA (DE) | 2010-03-17 | — | — | EP | claimed |
| EP-1949887-A2 | Cosmetic formulas for skin smoothing and tautening | Henkel AG & Co. KGaA (DE) | 2008-07-30 | — | — | EP | claimed |
| EP-1938789-A1 | Improvement of the skin friendliness of hyperemizing agents | Henkel AG & Co. KGaA (DE) | 2008-07-02 | — | — | EP | claimed |
| EP-1815843-A2 | Synergistic protein hydrolysate combinations for treating mature skin | Henkel KGaA (DE) | 2007-08-08 | — | — | EP | claimed |
| EP-1800119-A2 | COSMETIC AND DERMATOLOGICAL COMPOSITIONS CONTAINING ACTIVE SUBSTANCES FOR IMPROVING SENSORY PERCEPTION | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2007-06-27 | — | — | EP | claimed |
| EP-1776087-A1 | COSMETIC AND DERMATOLOGICAL COMPOSITIONS COMPRISING (2-HYDROXYETHYL)UREA | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2007-04-25 | — | — | EP | claimed |
| WO-2006042627-A2 | COSMETIC AND DERMATOLOGICAL COMPOSITIONS CONTAINING ACTIVE SUBSTANCES FOR IMPROVING SENSORY PERCEPTION | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2006-04-27 | — | — | WO | claimed |
| EP-1640041-A2 | Cosmetic and dermatological composition for the treatment of aging or photodamaged skin | Henkel Kommanditgesellschaft auf Aktien (DE) | 2006-03-29 | — | — | EP | claimed |
| WO-2006018198-A1 | COSMETIC AND DERMATOLOGICAL COMPOSITIONS COMPRISING (2-HYDROXYETHYL)UREA | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2006-02-23 | — | — | WO | claimed |
| EP-1430933-A2 | Cosmetic and pharmaceutical compositions comprising steroid sulfatase inhibitors and their use for the reduction of hair loss | Henkel Kommanditgesellschaft auf Aktien (DE) | 2004-06-23 | — | — | EP | claimed |
| EP-1428519-A2 | 5-Lipooxygenase inhibitors in deodorants and antiperspirants | Henkel Kommanditgesellschaft auf Aktien (DE) | 2004-06-16 | — | — | EP | claimed |
| EP-1428520-A2 | Lipase inhibitors in deodorants and antiperspirants | Henkel Kommanditgesellschaft auf Aktien (DE) | 2004-06-16 | — | — | EP | claimed |
| EP-1393518-A2 | ARYLSULFATASE-INHIBITORS IN DEODORANTS AND ANTIPERSPIRANTS | Henkel Kommanditgesellschaft auf Aktien (DE) | 2004-03-03 | — | — | EP | claimed |
| WO-2001099376-A2 | ARYLSULFATASE-INHIBITORS IN DEODORANTS AND ANTIPERSPIRANTS | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2001-12-27 | — | — | WO | claimed |
| US-20250367295-A1 | FAST-ACTING PLANT-BASED MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | SPOKE SCIENCES, INC. (US) | 2025-12-04 | — | — | US | disclosed |
| EP-3928776-B1 | FAST-ACTING PLANT-BASED MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | SPOKE SCIENCES INC (US) | 2025-11-12 | — | — | EP | disclosed |
| WO-2003097005-A1 | HIGHLY FOAMING CLEANSING GEL CONTAINING ACYLAMINO ACID SURFACTANTS | BEIERSDORF AG (DE) | 2003-11-27 | — | — | WO | disclosed |
| WO-2001099376-A2 | ARYLSULFATASE-INHIBITORS IN DEODORANTS AND ANTIPERSPIRANTS | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2001-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250367295-A1 | FAST-ACTING PLANT-BASED MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | SLC1A5, SLC43A1, SLC27A2 | NOD1 3604/4885SLC6A5 309/4885FAAH 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.